Clopidogrel Bisulfate
Product Images NDC 62034-015

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 62034-015). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Graphic-clopidogrel 75mg 100s (Label Clopidogreltabs 75mg Bpi(62034 015 77) Apotex(60505 0253 3) Rev1)

This is a description of a medication called Clopidogrel, which comes in tablet form, with a dosage of 75mg. The package contains one unit dose of the tablets, and each coated tablet contains 97.875mg of Clopidogrel Bisulfate, equivalent to 75mg of Clopidogrel Base. The medication is meant to be kept out of reach of children and stored at a controlled temperature of 15 to 30 degrees Celsius. The package includes an instructional leaflet for proper usage. The medication is produced by Apotex, and the package has a National Drug Code number of 62034-015-77.*

FDA Label Image

Clopiodgrel-01 (Image 01)

FDA Label Image

Figure-01 (Image 02)

Figure 1 shows the effect of co-administering proton pump inhibitors (PPls) on exposure to Clopidogrel Active Metabolite after multiple doses of Clopidogrel 75 mg. The graph displays mean and 90% confidence intervals for the effect on active metabolite AUC of co-administration with different PPls such as Destansoprazole, Pustoprzsle and Omepnzole. The change in relative to Clopidogrel administered alone is also shown.*

FDA Label Image

Figure2 (Image 03)

FDA Label Image

Figure 3 (Image 04)

FDA Label Image

Figure4 (Image 05)

The text provides a graph, figure 4, that shows the cumulative event rates for death in the COMMIT Study™. No further information is available.*

FDA Label Image

Figure5 (Image 06)

The text describes a figure which shows the cumulative event rates for the combined endpoint of re-infraction, stroke, or death in a study referred to as the COMMIT study. The figure includes a chart with the number of events and percentages of individuals who experienced the combined endpoint based on days since randomization. Some additional information about specific numbers and drugs used in the study is also included. The figure may be related to cardiology or cardiovascular research.*

FDA Label Image

Figure6 (Image 07)

This is a figure showing the effects of adding Clopidogrel to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups. The data is categorized by Baseline Svens Heterogeneity and Prognostic Index. There are also statistics on Fibrinolytic agent given, Metoprolol allocation, and Proportions. The figure also includes information on Three similar-sized prognostic index groups.*

FDA Label Image

Figure7 (Image 08)

FDA Label Image

Figure 8 (Image 09)

The text provides a figure and data from the CAPRIE study showing the event rate (%) for fatal or non-fatal vascular events. It is difficult to determine the exact meaning without additional context or clearer images.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.